Needham Reaffirms Their Buy Rating on Gamida Cell (GMDA)
August 15 2022 - 11:35AM
TipRanks
Needham analyst Gil Blum maintained a Buy rating on Gamida Cell
(GMDA - Research Report) today and set a price target of $12.00.
The company's shares opened today at $3.07.According to TipRanks,
Blum is an analyst with an average return of -2.3% and a 44.85%
success rate. Blum covers the Healthcare sector, focusing on stocks
such as Sarepta Therapeutics, CTI BioPharma, and Crispr
Therapeutics AG.Gamida Cell has an analyst consensus of Strong Buy,
with a price target consensus of $14.80, implying a 382.08% upside
from current levels. In a report released today, Piper Sandler also
maintained a Buy rating on the stock with a $8.00 price target.
https://www.tipranks.com/news/blurbs/needham-reaffirms-their-buy-rating-on-gamida-cell-gmda?utm_source=advfn.com&utm_medium=referral
Gamida Cell (NASDAQ:GMDA)
Historical Stock Chart
From Dec 2022 to Jan 2023
Gamida Cell (NASDAQ:GMDA)
Historical Stock Chart
From Jan 2022 to Jan 2023